Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 11, 2018

Primary Completion Date

July 30, 2019

Study Completion Date

September 30, 2019

Conditions
Depressive Disorder, MajorDepressive Disorder, Treatment-Resistant
Interventions
DRUG

REL-1017

REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.

DRUG

Placebo

Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.

Trial Locations (10)

30030

iResearch Atlanta, LLC, Decatur

30331

Atlanta Center for Medical Research, Atlanta

33012

Innovative Clinical Research, Inc, Hialeah

63141

St. Louis Clinical Trials, LLC, St Louis

72211

Woodland International Research Group, Little Rock

75080

Pillar Clinical Research, LLC, Richardson

92103

Artemis Institute for Clinical Research, San Diego

92845-2506

Collaborative Neuroscience Network, LLC, Garden Grove

08009

Hassman Research Institute, Berlin

45417-3445

Midwest Clinical Research Center, Dayton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Relmada Therapeutics, Inc.

INDUSTRY